Buscar
Mostrando ítems 1-10 de 49
In vitro assessment of anti-fibrotic drug activity does not predict in vivo efficacy in murine models of Duchenne muscular dystrophy
(2021)
Aim: Fibrosis is the most common complication from chronic diseases, and yet no therapy capable of mitigating its effects is available. Our goal is to unveil specific signaling regulating the fibrogenic process and to ...
Hepatic capillariasis in rats: a new model for testing antifibrotic drugs
(Braz J Med Biol Res, 2000)
Rats infected with the helminth Capillaria hepatica regularly develop
septal hepatic fibrosis that may progress to cirrhosis in a relatively
short time. Because of such characteristics, this experimental model
was selected ...
Hepatic capillariasis in rats: a new model for testing antifibrotic drugs
(Braz J Med Biol Res, 2000)
SURAMIN ATTENUATES DYSTROPHIN-DEFICIENT CARDIOMYOPATHY IN THE mdx MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY
(Wiley-blackwellHobokenEUA, 2013)
Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease
(2020-01-01)
Non-alcoholic fatty liver disease (NAFLD) affects around 25% of the worldwide population. Non-alcoholic steatohepatitis (NASH), the more progressive variant of NAFLD, is characterized by steatosis, cellular ballooning, ...